Lenvaxen contains lenvatinib, an oral kinase inhibitor used in specific cancer treatment settings. The 4 mg and 10 mg capsules are available strengths of lenvatinib. Its activity involves several receptor tyrosine kinases, including VEGFR1–3, FGFR1–4, PDGFRα, KIT, and RET. By affecting these signaling pathways, lenvatinib can interfere with processes involved in tumor growth and the formation of blood vessels that support tumors.
Approved Clinical Uses
Depending on the applicable regulatory authority and the patient’s diagnosis, lenvatinib may be used for progressive radioactive-iodine-refractory differentiated thyroid cancer. It is also used in combination with other medicines for certain patients with advanced renal cell carcinoma and advanced endometrial carcinoma. In addition, it is approved as a first-line treatment for unresectable hepatocellular carcinoma in specific clinical circumstances. Approved uses can vary between countries, so the relevant local prescribing information should always be followed.
Pharmacological and Safety Information
Lenvatinib is administered orally and can be taken with or without food. Its terminal elimination half-life is approximately 28 hours. Because treatment can cause clinically important adverse reactions, prescribing information recommends monitoring during therapy. Important warnings include hypertension, cardiac dysfunction, liver toxicity, kidney problems, proteinuria, diarrhea, bleeding, QT prolongation, hypocalcemia, impaired wound healing, and other serious reactions.
Why Clinical Supervision Matters
The appropriate lenvatinib regimen depends on the cancer type, treatment combination, organ function, and individual clinical circumstances. Dose interruptions or reductions may be required when significant adverse reactions occur. Lenvaxen 4 mg and 10 mg should therefore be used only according to a qualified prescriber’s instructions and the applicable official prescribing information.